Application of Nanotechnology in Drug Delivery Systems for Respiratory Diseases (Review)

Overview

Journal Mol Med Rep

Specialty Molecular Biology

Date 2021 Mar 24

PMID 33760125

Citations 17

Authors

Ming-Xin Luo

Shan Hua

Qi-Yun Shang

Affiliations

Soon will be listed here.

Abstract

Respiratory disease is a common disease with a high incidence worldwide, which is a serious threat to human health, and is considered a societal and economic burden. The application of nanotechnology in drug delivery systems has created new treatments for respiratory diseases. Within this context, the present review systematically introduced the physicochemical properties of nanoparticles (NPs); reviewed the current research status of different nanocarriers in the treatment of respiratory diseases, including liposomes, solid lipid nanocarriers, polymeric nanocarriers, dendrimers, inorganic nanocarriers and protein nanocarriers; and discussed the main advantages and limitations of therapeutic nanomedicine in this field. The application of nanotechnology overcomes drug inherent deficiencies to a certain extent, and provides unlimited potential for the development of drugs to treat respiratory diseases. However, most of the related research work is in the preclinical experimental stage and safety assessment is still a challenging task. Future studies are needed to focus on the performance modification, molecular mechanism and potential toxicity of therapeutic nanomedicine.

Citing Articles

Green Chemically Synthesized Iron Oxide Nanoparticles-Chitosan Coatings for Enhancing Strawberry Shelf-Life.

Sani A, Hassan D, Chanihoon G, Melo Maximo D, Sanchez-Rodriguez E Polymers (Basel). 2024; 16(23).

PMID: 39683984 PMC: 11644731. DOI: 10.3390/polym16233239.

Next-generation pediatric care: nanotechnology-based and AI-driven solutions for cardiovascular, respiratory, and gastrointestinal disorders.

de Alencar Morais Lima W, de Souza J, Garcia-Villen F, Loureiro J, Raffin F, Fernandes M World J Pediatr. 2024; 21(1):8-28.

PMID: 39192003 DOI: 10.1007/s12519-024-00834-x.

Nanomaterials-assisted gene editing and synthetic biology for optimizing the treatment of pulmonary diseases.

Lei L, Pan W, Shou X, Shao Y, Ye S, Zhang J J Nanobiotechnology. 2024; 22(1):343.

PMID: 38890749 PMC: 11186260. DOI: 10.1186/s12951-024-02627-w.

A novel therapeutic outlook: Classification, applications and challenges of inhalable micron/nanoparticle drug delivery systems in lung cancer (Review).

Xie L, Xie D, DU Z, Xue S, Wang K, Yu X Int J Oncol. 2024; 64(4).

PMID: 38391039 PMC: 10901537. DOI: 10.3892/ijo.2024.5626.

Recent Updates in Inhalable Drug Delivery System against Various Pulmonary Diseases: Challenges and Future Perspectives.

Chaudhary K, Singh K, Singh C Curr Drug Deliv. 2023; 21(10):1320-1345.

PMID: 37870055 DOI: 10.2174/0115672018265571231011093546.

References

Li B, Xie J, Yuan Z, Jain P, Lin X, Wu K . Mitigation of Inflammatory Immune Responses with Hydrophilic Nanoparticles. Angew Chem Int Ed Engl. 2018; 57(17):4527-4531. DOI: 10.1002/anie.201710068. View

Auria-Soro C, Nesma T, Juanes-Velasco P, Landeira-Vinuela A, Fidalgo-Gomez H, Acebes-Fernandez V . Interactions of Nanoparticles and Biosystems: Microenvironment of Nanoparticles and Biomolecules in Nanomedicine. Nanomaterials (Basel). 2019; 9(10). PMC: 6835394. DOI: 10.3390/nano9101365. View

Rudokas M, Najlah M, Albed Alhnan M, Elhissi A . Liposome Delivery Systems for Inhalation: A Critical Review Highlighting Formulation Issues and Anticancer Applications. Med Princ Pract. 2016; 25 Suppl 2:60-72. PMC: 5588529. DOI: 10.1159/000445116. View

Lee Y, Ko E, Kim K, Hwang H, Lee Y, Kwon Y . Cellular Immune Correlates Preventing Disease Against Respiratory Syncytial Virus by Vaccination with Virus-Like Nanoparticles Carrying Fusion Proteins. J Biomed Nanotechnol. 2018; 13(1):84-98. PMC: 5749259. DOI: 10.1166/jbn.2017.2341. View

Black K, Wang Y, Luehmann H, Cai X, Xing W, Pang B . Radioactive 198Au-doped nanostructures with different shapes for in vivo analyses of their biodistribution, tumor uptake, and intratumoral distribution. ACS Nano. 2014; 8(5):4385-94. PMC: 4358630. DOI: 10.1021/nn406258m. View

Lin X, Zuo Y, Gu N . Shape affects the interactions of nanoparticles with pulmonary surfactant. Sci China Mater. 2017; 58(1):28-37. PMC: 5523932. DOI: 10.1007/s40843-014-0018-5. View

Ngan C, Asmawi A . Lipid-based pulmonary delivery system: a review and future considerations of formulation strategies and limitations. Drug Deliv Transl Res. 2018; 8(5):1527-1544. DOI: 10.1007/s13346-018-0550-4. View

Murugan K, Choonara Y, Kumar P, Bijukumar D, du Toit L, Pillay V . Parameters and characteristics governing cellular internalization and trans-barrier trafficking of nanostructures. Int J Nanomedicine. 2015; 10:2191-206. PMC: 4370919. DOI: 10.2147/IJN.S75615. View

Senapati S, Mahanta A, Kumar S, Maiti P . Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduct Target Ther. 2018; 3:7. PMC: 5854578. DOI: 10.1038/s41392-017-0004-3. View

10.

Newman S . Delivering drugs to the lungs: The history of repurposing in the treatment of respiratory diseases. Adv Drug Deliv Rev. 2018; 133:5-18. DOI: 10.1016/j.addr.2018.04.010. View

11.

Pandey R, Sharma A, Zahoor A, Sharma S, Khuller G, Prasad B . Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother. 2003; 52(6):981-6. DOI: 10.1093/jac/dkg477. View

12.

Garbuzenko O, Mainelis G, Taratula O, Minko T . Inhalation treatment of lung cancer: the influence of composition, size and shape of nanocarriers on their lung accumulation and retention. Cancer Biol Med. 2014; 11(1):44-55. PMC: 3969800. DOI: 10.7497/j.issn.2095-3941.2014.01.004. View

13.

Bobo D, Robinson K, Islam J, Thurecht K, Corrie S . Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date. Pharm Res. 2016; 33(10):2373-87. DOI: 10.1007/s11095-016-1958-5. View

14.

Conti D, Brewer D, Grashik J, Avasarala S, da Rocha S . Poly(amidoamine) dendrimer nanocarriers and their aerosol formulations for siRNA delivery to the lung epithelium. Mol Pharm. 2014; 11(6):1808-22. PMC: 4051247. DOI: 10.1021/mp4006358. View

15.

Bakand S, Hayes A, Dechsakulthorn F . Nanoparticles: a review of particle toxicology following inhalation exposure. Inhal Toxicol. 2012; 24(2):125-35. DOI: 10.3109/08958378.2010.642021. View

16.

Fromen C, Robbins G, Shen T, Kai M, Ting J, DeSimone J . Controlled analysis of nanoparticle charge on mucosal and systemic antibody responses following pulmonary immunization. Proc Natl Acad Sci U S A. 2014; 112(2):488-93. PMC: 4299250. DOI: 10.1073/pnas.1422923112. View

17.

Yin Ng Z, Jin-Ying Wong , Panneerselvam J, Madheswaran T, Kumar P, Pillay V . Assessing the potential of liposomes loaded with curcumin as a therapeutic intervention in asthma. Colloids Surf B Biointerfaces. 2018; 172:51-59. DOI: 10.1016/j.colsurfb.2018.08.027. View

18.

Zhao L, Li Y, Pei D, Huang Q, Zhang H, Yang Z . Glycopolymers/PEI complexes as serum-tolerant vectors for enhanced gene delivery to hepatocytes. Carbohydr Polym. 2018; 205:167-175. DOI: 10.1016/j.carbpol.2018.10.036. View

19.

Patton J, Fishburn C, Weers J . The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc. 2005; 1(4):338-44. DOI: 10.1513/pats.200409-049TA. View

20.

Brown S, Nativo P, Smith J, Stirling D, Edwards P, Venugopal B . Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin. J Am Chem Soc. 2010; 132(13):4678-84. PMC: 3662397. DOI: 10.1021/ja908117a. View